Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...

About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with procedures ...

Today, a patient diagnosed with advanced prostate cancer has options. Doctors can offer a suite of androgen-suppressing drugs to extend his life. There are genetic tests that can show whether he’s a ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...

Urinary incontinence (UI) after radical prostatectomy is a common and distressing complication for men with prostate cancer.

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...

The marathon surgical session, conducted between 8 am and 5 pm, was led by Dr (prof) Santosh Kumar, with the procedures ...